Provenance Record

Well-structured News piece (Overview / What We Know / What We Don't Know) at 572 words, within the 400-1200 word News range. Clear, neutral, informative prose with appropriate technical context on antibody design and industry-wide AI drug discovery stats.

All 3 cited sources were fetched successfully (HTTP 200) and their local gzip snapshots verified: source-0.html.gz (SiliconANGLE, sha256 b39c9df...11f5bd, matches manifest), source-1.html.gz (BioSpace $400M Series C release, sha256 3010fc7...857a3a, matches manifest), source-2.html.gz (BioSpace Novartis collaboration release, sha256 635536e...989bf3d, matches manifest). Read full extracted text of all three. Core facts -- $400M raise, $3.8B valuation (nearly tripling the $1.3B December 2025 mark), Index Ventures-led round with Kleiner Perkins/Sequoia/Dimension, the full investor roster, the Meier CEO quote, the Pfizer licensing deal, the Eli Lilly customer agreement, the Novartis collaboration announcement, Fiona Marshall's quote, the Meier Novartis quote, undisclosed financial terms, the $20B industry investment figure and 173 AI-originated drug programs figure (both correctly sub-attributed to Excelra Knowledge Solutions and OncoDaily via SiliconANGLE) -- all check out against the snapshots. Two attribution/quote-fidelity issues found in the body (not headline/summary/lead), documented in findings above and filed as a corrections record: (1) the Chai-2 'zero-shot generative platform' quote and part of the extended investor list are attributed to SiliconANGLE but actually appear only in the BioSpace release; (2) the Novartis-collaboration timeline sentence paraphrases the BioSpace release while presented in quotation marks, and adds an unsupported/likely-incorrect year ('spring 2025' vs. the source's undated 'last spring', which — given the source's July 13, 2026 publish date — more plausibly means spring 2026).

No fabricated events, no invented sources, no bidirectional source-array gap (all 3 body URLs match article.sources exactly). The headline, summary, and Overview lead paragraph are each fully supported by the cited sources with no material errors. The two issues found are confined to secondary paragraphs in the body: a source-attribution mix-up (the underlying facts are true and appear in the article's own other cited source) and a paraphrase-as-quote with one likely-incorrect year. Neither issue changes the article's central thesis (a large up-round for an AI drug-design startup with growing pharma traction).

Substantively strong, accurately sourced article on a genuinely new topic. Headline, summary, and lead are solid. Two recoverable body-paragraph issues (source misattribution for an otherwise-true quote/list, and a paraphrase-as-quote with a likely-incorrect year) do not gut the article's thesis and can be honestly summarized in a public corrections note. Verdict: APPROVE_WITH_CORRECTIONS.